Hamster adipocyte alpha 2-adrenoceptor changes during fat mass modifications are not directly dependent on adipose tissue norepinephrine content.
It is questioned whether alterations of the sympathetic nervous system can explain the specific increment of the adipocyte alpha 2-adrenoceptor observed during white adipose tissue (WAT) enlargement and fat cell size increment. The impact of a 6-hydroxydopamine-induced sympathectomy, validated by determination of the WAT norepinephrine content, was tested on isolated white fat cell alpha 2-adrenoceptor function and binding [( 3H]RX 821002 and [3H]UK 14304 binding). Chemical sympathectomy of standard adult hamsters, neither alters the alpha 2-adrenergic-dependent antilipolysis nor the adipocyte alpha 2-adrenergic binding. A slight hypersensitivity of the beta 1-adrenergic lipolytic response was observed, without modification in beta-adrenergic binding [( 125I]cyanopindolol binding). Compared with controls, caloric restriction (10 days) of adult hamsters induced a large decrease in adipocyte alpha 2-adrenoceptor (P less than 0.001) with a parallel decrement in the mean fat cell size (P less than 0.001) and alpha 2-adrenergic responsiveness while there was no significant variation of the WAT norepinephrine content (on a per pad basis). 6-Hydroxydopamine treatment of the restricted animals (from day 6 to day 9) induced a higher preservation of adipocyte alpha 2-adrenoceptor density (P less than 0.001), no change in alpha 2-adrenergic responsiveness, and higher preservation of mean fat cell size (P less than 0.05) than in the restricted only animals. No significant modification in the beta-adrenergic binding was observed whatever the conditions. It was concluded that the specific increment in the adipocyte alpha 2-adrenoceptor during fat mass enlargement was not directly dependent on sympathetic nervous system alterations. Nevertheless, the sympathetic-dependent mobilization of the fat stores, after induction of caloric restriction, can indirectly modulate the alpha 2-adrenoceptor density in the adipocyte by promoting changes in white fat cell size.
Saulnier-Blache
J S
JS
Institut National de la Santé et de la Recherche Médicale (I.N.S.E.R.M. U. 317), Université Paul Sabatier, Toulouse, France.
Atgie
C
C
Carpene
C
C
Quideau
N
N
Lafontan
M
M
D000273:Adipose Tissue / Q000294:innervation / Q000378:metabolism*; D000316:Adrenergic alpha-Agonists / Q000378:metabolism; D000317:Adrenergic alpha-Antagonists; D000818:Animals; D000068438:Brimonidine Tartrate; D006224:Cricetinae; D004146:Dioxanes / Q000378:metabolism; D002149:Energy Intake; D005508:Food Deprivation; D006892:Hydroxydopamines; D019329:Idazoxan / Q000031:analogs & derivatives; D008066:Lipolysis; D008297:Male; D008647:Mesocricetus; D009638:Norepinephrine / Q000378:metabolism*; D016627:Oxidopamine; D010869:Pindolol / Q000031:analogs & derivatives / Q000378:metabolism; D011810:Quinoxalines / Q000378:metabolism; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D013563:Sympathectomy, Chemical
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D004146:Dioxanes; D006892:Hydroxydopamines; D011810:Quinoxalines; D011942:Receptors, Adrenergic, alpha; C047975:cyanopindolol; D000068438:Brimonidine Tartrate; D016627:Oxidopamine; D010869:Pindolol; C058525:2-methoxyidazoxan; D009638:Norepinephrine; D019329:Idazoxan